Holiday Notice: Expect delayed shipping. Orders ship 4/6.
FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION.

CJC-1295 with DAC — Published Research

Reviewed by: Dr. Sarah Chen, PharmD| Last updated: March 8, 2026|For laboratory reference only

← Back to CJC-1295 with DAC product page

Research Library

Published research on CJC-1295 with DAC — for educational purposes only

Drug Affinity Complex (DAC) Albumin-Binding Technology

The DAC technology utilizes a reactive maleimide linker attached to the peptide that covalently binds to Cys34 of circulating serum albumin. This prevents glomerular filtration (albumin MW ~66 kDa exceeds renal threshold) and protects the peptide from proteolysis. The conjugation reaction is essentially irreversible under physiological conditions. Pharmacokinetic studies in animal models show that >90% of CJC-1295-DAC becomes albumin-bound within minutes. Research compound — not for human use.

Jette L et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.” Endocrinology. 2005. PubMed

GHRH Receptor Pharmacology and GH/IGF-1 Axis

CJC-1295 is a modified GHRH(1-29) analog that activates the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor on anterior pituitary somatotrophs. Receptor activation stimulates Gαs-mediated cAMP production and subsequent GH gene transcription and secretory granule exocytosis. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) confer resistance to DPP-IV cleavage and improve receptor binding affinity compared to native GHRH(1-29). Research compound — not for human use.

Teichman SL et al. “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone.” J Clin Endocrinol Metab. 2006. PubMed

CJC-1295 in GHRH Knockout Mouse Models

Studies using GHRH knockout (GHRH-KO) mice—which have severe GH deficiency, dwarfism, and virtually undetectable IGF-1—demonstrated that CJC-1295 administration partially restored somatic growth. Treatment increased body weight, femur length, and pituitary GH mRNA expression. The results confirmed that the somatotroph population in GHRH-KO mice retained functional GHRH receptors capable of responding to exogenous GHRH analogs despite the absence of endogenous hypothalamic GHRH. Research compound — not for human use.

Alba M et al. “Administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006. PubMed

Disclaimer: All research citations are provided for educational purposes only. These references describe findings from in vitro and animal model studies. This information does not constitute medical advice and should not be interpreted as endorsement of any specific application.

Reviewed by

Dr. Sarah Chen, PharmD

Research pharmacologist specializing in peptide therapeutics. Reviews published clinical data and pharmacological research for accuracy and completeness.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD and Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published peer-reviewed research for educational purposes only. It is not medical advice and does not constitute a recommendation for any specific compound or protocol.